BR112021023737A2 - Composição farmacêutica e uso - Google Patents

Composição farmacêutica e uso

Info

Publication number
BR112021023737A2
BR112021023737A2 BR112021023737A BR112021023737A BR112021023737A2 BR 112021023737 A2 BR112021023737 A2 BR 112021023737A2 BR 112021023737 A BR112021023737 A BR 112021023737A BR 112021023737 A BR112021023737 A BR 112021023737A BR 112021023737 A2 BR112021023737 A2 BR 112021023737A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
blood
present
brain barrier
pharmaceutical
Prior art date
Application number
BR112021023737A
Other languages
English (en)
Inventor
Denis Barritault
Jérome Toutain
Myriam Bernaudin
Omar Touzani
Yacine Khelif
Original Assignee
Centre Nat Rech Scient
Denis Barritault
Organes Tissus Regeneration Reparation Remplacement
Univ Caen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Denis Barritault, Organes Tissus Regeneration Reparation Remplacement, Univ Caen filed Critical Centre Nat Rech Scient
Publication of BR112021023737A2 publication Critical patent/BR112021023737A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

composição farmacêutica e uso. a presente invenção refere-se a uma composição farmacêutica para sua aplicação como medicamento, em particular para uso para a proteção da barreira hematoencefálica e/ou para a reparação e/ou restauração da barreira hematoencefálica. a presente invenção pode ser aplicada especialmente nos campos terapêuticos, farmacêuticos e veterinários.
BR112021023737A 2019-05-27 2020-04-30 Composição farmacêutica e uso BR112021023737A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1905566A FR3096579B1 (fr) 2019-05-27 2019-05-27 composition pour la protection et la reparation de la barriere hematoencephalique (BHE)
PCT/EP2020/062081 WO2020239356A1 (fr) 2019-05-27 2020-04-30 Composition pour la protection et la reparation de la barriere hematoencephalique (bhe)

Publications (1)

Publication Number Publication Date
BR112021023737A2 true BR112021023737A2 (pt) 2022-02-01

Family

ID=68138337

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021023737A BR112021023737A2 (pt) 2019-05-27 2020-04-30 Composição farmacêutica e uso

Country Status (10)

Country Link
US (1) US20220152089A1 (pt)
EP (1) EP3976060A1 (pt)
JP (1) JP2022534278A (pt)
KR (1) KR20220042310A (pt)
CN (1) CN114206354B (pt)
AU (1) AU2020284406A1 (pt)
BR (1) BR112021023737A2 (pt)
CA (1) CA3141923A1 (pt)
FR (1) FR3096579B1 (pt)
WO (1) WO2020239356A1 (pt)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4021066A1 (de) * 1990-07-03 1992-01-09 Hoechst Ag Langzeitprophylaxe gegen erkrankungen, die durch viren oder durch unkonventionelle viren verursacht werden
FR2718025B1 (fr) * 1994-03-30 1996-06-21 Paris Val Marne Universite Médicament et composition pharmaceutique pour le traitement des lésions du système nerveux.
US6573251B2 (en) * 1994-03-30 2003-06-03 Denis Barritault Drug and pharmaceutical composition for the treatment of lesions of the nervous system and fractions enriched in heparan sulfate
FR2781485B1 (fr) 1998-07-21 2003-08-08 Denis Barritault Polymeres biocompatibles leur procede de preparation et les compositions les contenant
CA2397016C (en) * 2000-01-10 2011-03-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of disease
FR2832708B1 (fr) 2001-11-29 2004-02-13 Organes Tissus Regeneration Re Procede de sulfonation de composes comprenant des groupements hydroxyle (oh) libres ou des amines primaires ou secondaires
ES2552106T3 (es) 2003-10-28 2015-11-25 Organes Tissus Régénération Réparation Remplacement Polímeros biocompatibles para una composición médica
WO2008097563A1 (en) 2007-02-06 2008-08-14 The Board Of Trustees Of The Leland Stanford Junior University Methods for maintaining blood-brain barrier integrity in hypertensive subjects using a delta-pkc inhibitor
US8343942B2 (en) * 2008-04-04 2013-01-01 University Of Utah Research Foundation Methods for treating interstitial cystitis
CN101632728B (zh) 2008-07-21 2013-08-07 河北以岭医药研究院有限公司 一种中药组合物在制备保护血脑屏障的药物中的应用
EP3097928A1 (fr) * 2015-05-28 2016-11-30 Organes Tissus Régénération Réparation Remplacement Composition pour le traitement des lesions cerebrales
EP3097922A1 (fr) * 2015-05-28 2016-11-30 Denis Barritault Composition pour le traitement des lesions tissulaires
CN105148276B (zh) 2015-09-22 2018-11-20 深圳市第二人民医院 抑制Claudin-5降解阻止缺血性血脑屏障损伤的保护剂
WO2018207792A1 (ja) 2017-05-12 2018-11-15 花王株式会社 血液脳関門保護剤

Also Published As

Publication number Publication date
CN114206354A (zh) 2022-03-18
EP3976060A1 (fr) 2022-04-06
KR20220042310A (ko) 2022-04-05
US20220152089A1 (en) 2022-05-19
AU2020284406A1 (en) 2022-01-06
CN114206354B (zh) 2023-12-29
CA3141923A1 (fr) 2020-12-03
WO2020239356A1 (fr) 2020-12-03
FR3096579A1 (fr) 2020-12-04
JP2022534278A (ja) 2022-07-28
FR3096579B1 (fr) 2023-05-05

Similar Documents

Publication Publication Date Title
BR112018077457A2 (pt) composição farmacêutica para evitar ou tratar hiperinsulinismo congênito e seu método, hipoglicemia e seu método, síndrome metabólica e seu método e peptídeo isolado
BR112015011171A2 (pt) compostos de pirrolopirimidina como inibidores da quinase
CL2018000299A1 (es) Composiciones con potenciadores de impregnacion para el suministro de fármacos.
BR112018070549A2 (pt) degradantes de proteína mdm2
BR112015007659A2 (pt) mecanismos químicos e métodos para o uso dos mesmos, especialmente na injeção de fluidos altamente viscosos
BR112018008676A2 (pt) proteínas de fusão de fgf21 de ação prolongada e composição farmacêutica compreendendo as mesmas
BR112018008684A2 (pt) formulações de toxina botulínica injetáveis e processos de uso das mesmas com longa duração do efeito terapêutico ou cosmético
BR112018072545A2 (pt) inibidores da arginase e suas aplicações terapêuticas
BR112018002342A2 (pt) polímeros furtivos intrinsecamente desordenados e geneticamente modificados para entrega e métodos para uso dos mesmos
BR112014009415A2 (pt) inibidores de arginase e suas aplicações terapêuticas
BR112015030315A2 (pt) derivado de 4-alquinilimidazol e medicamento compreendendo o mesmo como ingrediente ativo
BR112020019875A8 (pt) composições tópicas para alívio da dor
BR112015017451A2 (pt) formulações farmacêuticas resistentes à violação
CR11418A (es) Trans-clomifeno para el sindrome metabolico
BR112015026247A8 (pt) composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit
BR112013017953A2 (pt) Composição farmacêutica, formulação tópica, método, e, composição fotossensibilizadora
BR112015017246A2 (pt) formulação farmacêutica que compreende um corticosteroide insolúvel e um corticosteroide solúvel
BR112014027995A2 (pt) uso de seaprose para remover biopelícula bacteriana
BR112012013164A2 (pt) composições farmacêuticas para o estímulo de células-tronco
BR112012022243A8 (pt) Uso de um inibidor de autofagia baseado em tioxantona e de um composto indutor de autofagia para terapia de câncer, composição farmacêutica e kit farmacêutico
BR112017028137A2 (pt) agente terapêutico para fibrose
BR112013010829B8 (pt) Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação
BRPI0916885B8 (pt) composição farmacêutica
AR114325A1 (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
BR112023006024A2 (pt) Terapias de imuno-oncologia com conjugados de il-2